NCT05824494View on ClinicalTrials.gov

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Uterine Cervical NeoplasmsCancer of CervixCervical CancerCervical NeoplasmsUterine Cervical CancerCancer of the Uterine Cervix
Interventions
DRUG

Cadonilimab

Cadonilimab 10mg/kg,every 3 weeks,IV infusion

DRUG

Nab paclitaxel

Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion

Sponsors

Collaborators (1)

Akeso
All Listed Sponsors
collaborator

Akeso

INDUSTRY

lead

Women's Hospital School Of Medicine Zhejiang University

OTHER

NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter